
Poseida (PSTX): April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Poseida Therapeutics (NASDAQ:PSTX) is expected to release results from the phase 1 study using P-BCMA-ALLO1 for the treatment of patients with relapsed or refractory